Clicky

VG Life Sciences Inc(VGLS)

Description: VG Life Sciences Inc. is a biotechnology company. The Company is engaged in developing transformative therapies to treat drug-resistant cancers, infectious diseases and autoimmune diseases caused by chronic inflammation. The Company operates as a drug discovery and development company researching two core technologies: Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT). The Company's MDT compounds impede tumor cells' ability to meet their energy requirements, leaving cancer cells vulnerable to cancer-killing agents. Its autoimmune therapy, TPT, eliminates a subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. Its peptides are designed to function in all Major Histocompatibility Complex II (MHC-II) phenotypes. It also has a drug research program in pre-clinical stages, a TPT therapy for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) using VG1177.


Keywords: Medicine Biotechnology Cancer Infectious Diseases Immunology Drug Discovery Tumor Autoimmune Disease Inflammation Peptides Autoimmunity HIV/Aids Deficiency Immunodeficiency Core Technologies Autoimmune And Infectious Diseases Chronic Inflammation Sjögren Syndrome Primary Immunodeficiency Tpt Tumor Cells Autoimmune And Infectious Disease Energy Requirements Peptide Technology

Home Page: www.vglifesciences.com

121 Gray Avenue
Santa Barbara, CA 93101
United States
Phone: 805 879 9000


Officers

Name Title
Mr. Haig Keledjian Co-Founder, Chairman, CEO, Pres, VP of R&D, CFO and Sec.
Dr. M. Karen Newell-Rogers Chief Scientist
Robert A. Forrester Corp. Counsel
Mr. Robert Berliner Consultant & Advisory Board Member

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 32.3803
Price-to-Sales TTM: 0
IPO Date: 1999-11-16
Fiscal Year End: December
Full Time Employees: 1
Back to stocks